Table 6.
Lipid and glucose baseline, post (6 or 12 weeks) and change data after placebo or SXRG84 treatment (Study 2). Data are presented as median (25th and 75th percentile). AA = Placebo for 6 weeks; AB = Placebo for 6 weeks then SXRG treatment for 6 weeks; BB = SXRG treatment for 6 weeks; BA = SXRG treatment for 6 weeks then placebo for 6 weeks.
| AA Baseline to 6 weeks (Placebo) n = 30 |
AB Baseline to 12 weeks (Placebo then Active) n = 30 |
BB Baseline to 6 weeks (Active) n = 34 |
BA Baseline to 12 weeks (Active then Placebo) n = 34 |
p-Value * | |
|---|---|---|---|---|---|
| Total Cholesterol (mmol/L) | |||||
| Baseline | 5.2 (4.5, 5.9) | 5.2 (4.5, 5.9) | 5.2 (4.5, 6.1) | 5.2 (4.5, 6.1) | 0.697 |
| Post | 4.6 (3.9, 5.4) | 4.8 (4.2, 5.7) | 5.3 (4.2, 5.9) | 5.0 (4.4, 5.9) | 0.120 |
| Change | −0.3 (−1.0, 0.1) | −0.1 (−0.7, 0.6) | −0.1 (−0.6, 0.4) | −0.3 (−1.0, 0.2) | |
| HDL Cholesterol (mmol/L) | |||||
| Baseline § | 1.3 (1.0, 1.6) | 1.3 (1.0, 1.6) | 1.3 (0.9, 1.8) | 1.3 (0.9, 1.8) | 0.810 |
| Post | 1.1 (1.0, 1.7) | 1.2 (1.0, 1.7) | 1.3 (0.9, 1.9) | 1.2 (0.9, 1.6) | 0.493 |
| Change | −0.0 (−0.2, 0.1) | −0.1 (−0.3, 0.2) | −0.0 (−0.2, 0.1) | −0.2 (−0.3, 0.1) | |
| Triglycerides (mmol/L) | |||||
| Baseline § | 1.0 (0.7, 1.2) | 1.0 (0.7, 1.2) | 1.2 (0.8, 1.8) | 1.2 (0.8, 1.8) | 0.112 |
| Post | 0.8 (0.7, 1.3) | 1.1 (0.7, 1.3) | 1.0 (0.8, 1.4) | 1.0 (0.8, 1.8) | 0.663 |
| Change | −0.1 (−0.3, 0.2) | 0.0 (−0.2, 0.3) | −0.1 (−0.4, 0.2) | −0.1 (−0.4, 0.1) | |
| Non-HDL Cholesterol (mmol/L) | |||||
| Baseline | 3.7 (3.0, 4.5) | 3.7 (3.0, 4.5) | 4.0 (3.1, 4.4) | 4.0 (3.1, 4.4) | 0.651 |
| Post | 3.4 (2.6, 3.9) | 3.6 (2.7, 4.3) | 3.8 (3.0, 4.6) | 3.7 (3.3, 4.3) | 0.086 |
| Change | −0.3 (−0.9, 0.1) | −0.1 (−0.7, 0.6) | 0.0 (−0.4, 0.3) | −0.2 (−0.7, 0.4) | |
| LDL Cholesterol (mmol/L) | |||||
| Baseline | 3.3 (2.6, 3.9) | 3.3 (2.6, 3.9) | 3.3 (2.6, 3.9) | 3.3 (2.6, 3.9) | 0.906 |
| Post | 2.9 (2.2, 3.4) | 3.2 (2.2, 3.9) | 3.4 (2.4, 3.7) | 3.2 (2.6, 3.7) | 0.103 |
| Change | −0.3 (−0.8, 0.1) | −0.2 (−0.7, 0.5) | −0.1 (−0.5, 0.3) | −0.1 (−0.6, 0.3) | |
| Fasting Glucose (mmol/L) | |||||
| Baseline ¥ | 4.5 (4.1, 5.3) | 4.5 (4.1, 5.3) | 4.9 (4.6, 5.3) | 4.9 (4.6, 5.3) | 0.071 |
| Post | 4.5 (4.1, 5.0) | 4.8 (4.1, 5.7) | 5.0 (4.2, 5.5) | 4.8 (4.3, 5.5) | 0.369 |
| Change | −0.1 (−0.4, 0.4) | 0.2 (−0.4, 1.0) | −0.0 (−0.5, 0.4) | −0.1 (−0.8, 0.3) | |
| 2-h Glucose Response to OGTT (mmol/L) | |||||
| Baseline ¥ | 4.9 (4.1, 5.7) | 4.9 (4.1, 5.7) | 4.8 (4.0, 6.1) | 4.8 (4.0, 6.1) | 0.844 |
| Post | 4.5 (4.2, 5.7) | 5.1 (4.3, 5.8) | 4.5 (3.8, 5.9) | 5.2 (4.0, 6.8) | 0.629 |
| Change | 0.0 (−0.8, 0.5) | 0.0 (−0.5, 0.6) | −0.1 (−1.0, 1.0) | 0.1 (−1.1, 1.2) |
Change determined by median post value (6 or 12 weeks) minus median baseline value. * p-value at baseline determined by T-test on normal, log-transformed (§), or Wilcoxon signed rank test (¥) between the two baseline regime groups. p-value for post measure determined by ANCOVA using absolute data from 6 weeks (for placebo and active group) and 12 weeks (for placebo then active group and active then placebo group) using baseline data as a covariate.